American Pharmaceutical Company Vivus, Inc. has entered into a settlement agreement with Dr Reddy's Laboratories Limited in a patent infringement litigation related to weight management drug Qsymia (phentermine and topiramate extended-release capsules).
Enforcement Report - Week of August 23, 2017
Zydus Pharm’s Generic Phentermine Hydrochloride Receives Approval In US
https://www.flickr.com/photos/pedrosimoes7/
Polygen's Generic Phentermine HCL Receiives Approval In US
Avanthi Inc Generic Phentermine Hydrochloride Approved In US
PD-Rx Pharmaceuticals, Inc. recalls Phentermine Hydrochloride Capsules, USP, 15 mg due to Failed impurities specifications
Analysis from business intelligence provider GBI Research — Frontier Pharma: Obesity — Identifying and Commercializing First-in-Class Innovation — states that despite the current market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, with 39% of the pipeline products with disclosed molecular targets classified as first-in-class.
PBM giants Express Scripts ($ESRX) and CVS Health ($CVS) have so far found formulary exclusions an effective way to manage drug costs. And unfortunately for pharma companies, that tactic is catching on.
Nine hundred sales reps are out in the field promoting Orexigen's ($OREX) obesity med Contrave, thanks to the company's marketing partner, Takeda. But for what?